Neuromuscular Blockade
Conditions
Keywords
Rocuronium, Pharmacokinetics, Pharmacodynamics
Brief summary
The purpose of this study is characterize the dose-effect relationship of rocuronium bromide at the adductor pollicis and masseter muscles using an pharmacokinetic-pharmacodynamic (PKPD) model. The hypothesis is that masseter muscle has a greater sensitivity to the neuromuscular blockers (rocuronium), faster onset and slower recovery profile than the adductor pollicis muscle.
Interventions
DRUGRocuronium Bromide
Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.
Sponsors
Pontificia Universidad Catolica de Chile
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Scheduled for elective surgery under general anesthesia.
Exclusion criteria
* Pregnancy. * Body mass index (BMI) \>25 kg/m2. * Anticipated difficult airway. * Surgery associated with great volume loss. * Presence of any neuromuscular, hepatic, renal, cardiac or respiratory disease. * Previous history of neuromuscular blockade allergy, and/or administration of drugs known to interfere with neuromuscular blockade
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| strength measuring 2 acceleromyograph. One Placed at the masseter muscle and the other one at the adductor pollicis muscle. | 60 minutes |
| Measure blood concentrations after administration rocuronium | 120 minutes |
Outcome results
None listed